JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265114

Human USB1 (C16orf57) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

USB1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

C16orf57, CP057_HUMAN, Chromosome 16 open reading frame 57, FLJ13154, UPF0406 protein C16orf57

1 Images
Sanger Sequencing - Human USB1 (C16orf57) knockout HeLa cell line (AB265114)
  • Sanger seq

Unknown

Sanger Sequencing - Human USB1 (C16orf57) knockout HeLa cell line (AB265114)

Homozygous : 1 bp insertion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265114-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265114-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265114 Human USB1 (C16orf57) knockout HeLa cell line", "number":"AB265114-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265114-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265114-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265114 Human USB1 (C16orf57) knockout HeLa cell line", "number":"AB265114-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265114-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265114 Human USB1 (C16orf57) knockout HeLa cell line", "number":"AB265114-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265114-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265114 Human USB1 (C16orf57) knockout HeLa cell line", "number":"AB265114-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
USB1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The C16orf57 protein also referred to as USB1 functions as a phosphodiesterase that removes the 2'3'-cyclic phosphate ends of spliceosomal U6 snRNA transforming them into 3'-phosphate ends. The molecular mass of C16orf57 is approximately 39 kDa. It is expressed in a variety of tissues including the liver heart and pancreas. This protein is important in RNA processing and ensures the stability and proper function of U6 snRNA an essential component of the spliceosome involved in pre-mRNA splicing.
Biological function summary

C16orf57 plays an important role in RNA metabolism. It is part of the RNA processing machinery and assists in maintaining the RNA molecules necessary for the extrusion of introns and ligation of exons. By contributing to RNA stability C16orf57 ensures efficient gene expression and protein synthesis. C16orf57 works closely with other components of the spliceosomal complex facilitating the removal of non-coding regions and proper coding sequence assembly.

Pathways

C16orf57 significantly affects the splicing and processing of RNA contributing to the splicing machinery pathway. This pathway is essential for accurate gene expression and involves interaction with proteins like SART3 further impacting the assembly and function of spliceosomal small nuclear ribonucleoproteins (snRNPs). Additionally the C16orf57 pathway connects tightly with RNA processing pathways which are necessary for converting pre-mRNA into mature mRNA.

Malfunction or deficiency of C16orf57 has been connected with poikiloderma with neutropenia (PN) a genetic condition that affects skin pigmentation and immune function. C16orf57 mutations also associate with dyskeratosis congenita a disorder affecting various tissues due to defective telomere maintenance. In these conditions C16orf57 impacts TBX1 and DKC1 proteins which participate in overlapping pathways involving telomeres and cellular proliferation further implicating C16orf57 in pathophysiological processes.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com